{"id":"NCT03486457","sponsor":"Pfizer","briefTitle":"Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB (CP-690,550) IN CHINESE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE CONVENTIONAL SYNTHETIC DMARD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-10","primaryCompletion":"2021-04-28","completion":"2021-04-28","firstPosted":"2018-04-03","resultsPosted":"2024-02-08","lastUpdate":"2024-02-08"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Tofacitinib","otherNames":[]}],"arms":[{"label":"Treatment Sequence A","type":"EXPERIMENTAL"},{"label":"Treatment Sequence B","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 3","timeFrame":"Month 3","effectByArm":[{"arm":"Tofacitinib","deltaMin":38.24,"sd":null},{"arm":"Placebo Then Tofacitinib","deltaMin":5.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":38,"countries":["China"]},"refs":{"pmids":["40241921","36720560"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=A3921234"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":136},"commonTop":["Upper respiratory tract infection","Blood creatine phosphokinase increased","Hyperlipidaemia","Alanine aminotransferase increased","Diarrhoea"]}}